Literature DB >> 16183422

Medication-related problems in ambulatory hemodialysis patients: a pooled analysis.

Harold J Manley1, Carrie A Cannella, George R Bailie, Wendy L St Peter.   

Abstract

BACKGROUND: Medication-related problems are common in hemodialysis (HD) patients. These patients often require 12 medications to treat 5 to 6 comorbid conditions. Medication-related problem research reports cannot be generalized to the entire HD population because data are obtained from single centers and limited numbers of patients. We conducted a pooled analysis to gain additional insight into the frequency, type, and severity of medication-related problems and extrapolated the data to the entire US HD population.
METHODS: Articles were identified through a MEDLINE search (1962 to March 2004). Seven studies were included in the analysis. Medication-related problems were categorized into the following 9 categories: indication without drug therapy, drug without indication, improper drug selection, subtherapeutic dosage, overdosage, adverse drug reaction, drug interaction, failure to receive drug, and inappropriate laboratory monitoring. A medication-related problem appearance rate was determined.
RESULTS: We identified 1,593 medication-related problems in 395 patients (51.2% men; age, 52.4 +/- 8.2 years; 42.7% with diabetes). The most common medication-related problems found were inappropriate laboratory monitoring (23.5%) and indication without drug therapy (16.9%). Dosing errors accounted for 20.4% of medication-related problems (subtherapeutic dosage, 11.2%; overdosage, 9.2%). The medication-related problem appearance rate was 5.75e(-0.37x), where x equals number of months of follow-up (P = 0.02).
CONCLUSION: HD patients experience ongoing medication-related problems. Reduction in medication-related problems in dialysis patients may improve quality of life and result in decreased morbidity and mortality. Pharmacists are uniquely trained to detect and manage medication-related problems. Pharmacists should be an integral member of the dialysis health care team.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16183422     DOI: 10.1053/j.ajkd.2005.07.001

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  42 in total

Review 1.  Opioid and benzodiazepine use in end-stage renal disease: a systematic review.

Authors:  Ahraaz Wyne; Raman Rai; Meaghan Cuerden; William F Clark; Rita S Suri
Journal:  Clin J Am Soc Nephrol       Date:  2010-11-11       Impact factor: 8.237

2.  Medication reconciliation and therapy management in dialysis-dependent patients: need for a systematic approach.

Authors:  Amy Barton Pai; Katie E Cardone; Harold J Manley; Wendy L St Peter; Rachel Shaffer; Michael Somers; Rajnish Mehrotra
Journal:  Clin J Am Soc Nephrol       Date:  2013-08-29       Impact factor: 8.237

3.  The missing piece: Clinical pharmacists enhancing the interprofessional nephrology clinic model.

Authors:  Chelsea E Hawley; Laura K Triantafylidis; Julie M Paik
Journal:  J Am Pharm Assoc (2003)       Date:  2019-06-21

4.  Standards of clinical practice for renal pharmacists.

Authors:  Colette B Raymond; Lori D Wazny; Amy R Sood
Journal:  Can J Hosp Pharm       Date:  2013-11

5.  Evaluation of a training and communication-network nephrology program for community pharmacists.

Authors:  Lyne Lalonde; Michelle Normandeau; Diane Lamarre; Anne Lord; Djamal Berbiche; Louise Corneille; Louis Prud'homme; Marie-Claude Laliberté
Journal:  Pharm World Sci       Date:  2008-09-19

6.  The clinical pharmacist's contributions within the multidisciplinary patient care team of an intern nephrology ward.

Authors:  Gunar Stemer; Rosa Lemmens-Gruber
Journal:  Int J Clin Pharm       Date:  2011-08-10

7.  Telephone-adapted mindfulness-based stress reduction (tMBSR) for patients awaiting kidney transplantation: Trial design, rationale and feasibility.

Authors:  Maryanne Reilly-Spong; Diane Reibel; Terry Pearson; Pat Koppa; Cynthia R Gross
Journal:  Contemp Clin Trials       Date:  2015-04-03       Impact factor: 2.226

8.  Medication Exposure and Health Outcomes in Older Patients with End-Stage Kidney Disease: A Prospective Study Undertaken in New Zealand.

Authors:  Sashika Samaranayaka; Robert J Walker; Ari Samaranayaka; Sarah Derrett; John W B Schollum
Journal:  Drugs Aging       Date:  2018-11       Impact factor: 3.923

9.  Detection of prescription errors by a unit-based clinical pharmacist in a nephrology ward.

Authors:  Ghazal Vessal
Journal:  Pharm World Sci       Date:  2009-10-17

10.  ESRD impairs nonrenal clearance of fexofenadine but not midazolam.

Authors:  Thomas D Nolin; Reginald F Frye; Phuong Le; Hooman Sadr; Judith Naud; Francois A Leblond; Vincent Pichette; Jonathan Himmelfarb
Journal:  J Am Soc Nephrol       Date:  2009-08-20       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.